By Associate Professor Megan Amanda Crumbaker

Journal articles

Crumbaker M; Chan EKF; Gong T; Corcoran N; Jaratlerdsiri W; Lyons RJ; Haynes AM; Kulidjian AA; Kalsbeek AMF; Petersen DC; Stricker PD; Jamieson CAM; Croucher PI; Hovens CM; Joshua AM; Hayes VM, 2020, 'The impact of whole genome data on therapeutic decision‐making in metastatic prostate cancer: A retrospective analysis', Cancers, 12, http://dx.doi.org/10.3390/cancers12051178

Emmett L; Pathmanandavel S; Nguyen A; Crumbaker M; Yam AOW; Chan WL; Fullard K; Ho B; Azad A; Joshua AM, 2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 120 - 120, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.120

Quah GT; Espinoza D; Arasaratnam M; Crumbaker M; Balakrishnar B; Brooks A; Lau H; Patel M; Bariol S; Gurney H, 2020, '212P Stage I non-seminoma testicular cancer: Adjuvant management and outcomes', Annals of Oncology, 31, pp. S1323 - S1323, http://dx.doi.org/10.1016/j.annonc.2020.10.223

Quah GT; Espinoza D; Crumbaker M; Balakrishnar B; Arasaratnam M; Bariol S; Brooks A; Lau H; Patel M; Gurney H, 2020, '213P Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance', Annals of Oncology, 31, pp. S1323 - S1323, http://dx.doi.org/10.1016/j.annonc.2020.10.224

Bhatnagar A; McKay MJ; Thaysen-Andersen M; Arasaratnam M; Crumbaker M; Gurney H; Molloy MP, 2019, 'Bioanalytical evaluation of dried plasma spots for monitoring of abiraterone and ∆(4)-abiraterone from cancer patients', Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences, 1126-1127, http://dx.doi.org/10.1016/j.jchromb.2019.121741

Crumbaker M; Wong J; Joshua AM; Spigelman AD, 2019, 'Outcomes of universal germline testing for men with prostate cancer in an Australian tertiary center', Asia Pacific Journal of Clinical Oncology, 15, pp. 257 - 261, http://dx.doi.org/10.1111/ajco.13148

Arasaratnam M; Crumbaker M; Bhatnagar A; McKay MJ; Molloy MP; Gurney H, 2019, 'Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer', Cancer Chemotherapy and Pharmacology, 84, pp. 139 - 146, http://dx.doi.org/10.1007/s00280-019-03862-x

Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM, 2019, 'Results of a Prospective Phase 2 Pilot Trial of 177 Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression', Clinical Genitourinary Cancer, 17, pp. 15 - 22, http://dx.doi.org/10.1016/j.clgc.2018.09.014

Crumbaker M; Emmett L; Horvath LG; Joshua AM, 2019, 'Exceptional response to 177lutetium prostate-specific membrane antigen in prostate cancer harboring DNA repair defects', JCO Precision Oncology, 3, pp. 1 - 5, http://dx.doi.org/10.1200/PO.18.00237

Emmett L; Yin C; Crumbaker M; Hruby G; Kneebone A; Epstein R; Nguyen Q; Hickey A; Ihsheish N; O'Neill G; Horvath L; Chalasani V; Stricker P; Joshua AM, 2019, 'Rapid modulation of PSMA expression by androgen deprivation: Serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade', Journal of Nuclear Medicine, 60, pp. 950 - 954, http://dx.doi.org/10.2967/jnumed.118.223099

Bhatnagar A; McKay MJ; Crumbaker M; Ahire K; Karuso P; Gurney H; Molloy MP, 2018, 'Quantitation of the anticancer drug abiraterone and its metabolite Δ(4)-abiraterone in human plasma using high-resolution mass spectrometry', Journal of Pharmaceutical and Biomedical Analysis, 154, pp. 66 - 74, http://dx.doi.org/10.1016/j.jpba.2018.03.012

Arasaratnam M; Balakrishnar B; Crumbaker M; Turner S; Hayden A; Brooks A; Patel M; Gurney H, 2018, 'Patterns of care and outcome of germ cell tumours (GCT) in an Australian high-volume centre.', JOURNAL OF CLINICAL ONCOLOGY, 36, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.e16534

Crumbaker M; Savdie R; Joshua AM, 2018, 'Refining the Assessment and Implications of AR-V7 in Castrate-resistant Prostate Cancer', European Urology, 73, pp. 736 - 737, http://dx.doi.org/10.1016/j.eururo.2017.11.005

Crumbaker M; Guminski A; Gurney H; Sabanathan D; Wong S; Pavlakis N, 2018, 'Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia', Asia Pacific Journal of Clinical Oncology, 14, pp. e45 - e49, http://dx.doi.org/10.1111/ajco.12686

Crumbaker M; Gurney H, 2017, 'Dose considerations for anti-cancer drugs in metastatic prostate cancer', Prostate, 77, pp. 1199 - 1204, http://dx.doi.org/10.1002/pros.23378

Crumbaker M; Khoja L; Joshua AM, 2017, 'AR signaling and the PI3K pathway in prostate cancer', Cancers, 9, pp. 34, http://dx.doi.org/10.3390/cancers9040034

Mersiades A; Crumbaker M; Gao B; Nagrial A; Hui R, 2017, 'P3.02c-033 Patterns of Progression and Management of Acquired Resistance to Anti-PD-1 Antibodies in Advanced Non-Small Cell Lung Cancer', Journal of Thoracic Oncology, 12, pp. S1293 - S1293, http://dx.doi.org/10.1016/j.jtho.2016.11.1828

Crumbaker M; Carlino M; Hui R; Mersiades A; Gurney H; Todd J; Gao B; Nagrial A, 2016, '471P Baseline full blood count parameters as predictors of response to PD-1 inhibition in advanced NSCLC', Annals of Oncology, 27, pp. ix151 - ix151, http://dx.doi.org/10.1016/s0923-7534(21)00629-3

Crumbaker M; Carlino M; Hui R; Mersiades A; Gurney H; Todd J; Gao B; Nagrial A, 2016, '471P Baseline full blood count parameters as predictors of response to PD-1 inhibition in advanced NSCLC', Annals of Oncology, 27, http://dx.doi.org/10.1093/annonc/mdw594.035

Chan D; McLachlan JM; Crumbaker M; Marx GM, 2015, 'Pretreatment neutrophil/lymphocyte ratio (NLR) prior to steroids as a prognostic factor in metastatic castrate refractory prostate cancer (mCRPC) patients treated with taxanes.', JOURNAL OF CLINICAL ONCOLOGY, 33, http://dx.doi.org/10.1200/jco.2015.33.7_suppl.273

McLachlan JM; Chan DL; Crumbaker MA; Marx GM, 2015, 'Neutrophil-lymphocyte ratio prior to steroids as a prognostic marker in men with metastatic castration-resistant prostate cancer', Cancer Treatment Communications, 4, pp. 81 - 85, http://dx.doi.org/10.1016/j.ctrc.2015.06.001

Back to profile page